Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Drug manufacturer Novo Nordisk announced a new experimental weight-loss pill to treat obesity in development called amycretin ...

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

The drug, called amycretin, helped volunteer patients lose a whopping 13 percent of their body weight over just 12 weeks. That means the new pill may be even more effective than the company's ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Why? Results from a Phase I trial of a new amycretin pill indicate that a highly effective and less intrusive weight loss drug is on the way, providing an alternative to the injection-based Ozempic.

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Analysts led by Prakhar Agrawal noted that Novo Nordisk has not launched an oral version of its semaglutide despite a positive Phase 3 trial and is awaiting subcutaneous amycretin data before ...

It also has another pill, amycretin. A phase 1 trial of amycretin released in September showed promising results. Meanwhile, Eli Lilly has orforglipron, an oral GLP-1 in phase 3. At the Seeking ...

Medscape Medical News, September 12, 2024 EASD 2024 'Remarkable' Weight Loss With Novel Oral Combo in Phase 1 Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable ...